Oronsky B et al (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12):991–1002

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tong JH, Yeung SF, Chan AWH et al (2016) MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis. Clin Cancer Res 22:3048–3056

Article  PubMed  CAS  Google Scholar 

Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W (2000) Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol 149:1419–1432

Article  PubMed  PubMed Central  CAS  Google Scholar 

Baltschukat S et al (2019) Capmatinib (INC280) is active against models of non-small cell lung cancer and other cancer types with defined mechanisms of MET activation. Clin Cancer Res 25(10):3164–3175

Article  PubMed  CAS  Google Scholar 

Wolf J, Seto T, Han JY et al (2020) Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 383:944–957

Article  PubMed  CAS  Google Scholar 

Daniel SL et al (2022) Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report and review of literature. Cancer Biol Thor 23(1):112–116

Article  Google Scholar 

Manisha H et al (2021) Neuroendocrine and adrenal tumors, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 19(7):869–868

Google Scholar 

Awad MM, Oxnard GR, Jackman DM et al (2016) MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression. J Clin Oncol 34:721–730

Article  PubMed  CAS  Google Scholar 

Frampton GM, Ali SM, Rosenzweig M et al (2015) Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5(8):850–859

Article  PubMed  CAS  Google Scholar 

Paik PK, Felip E, Veillon R et al (2020) Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. N Engl J Med 383(10):931–943

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anthony T (2022) Response to capmatinib in a MET fusion-positive cholangiocarcinoma. Oncologist 28(1):80–83

Google Scholar 

Faivre SJ et al (2021) Activity of tepotinib in hepatocellular carcinoma (HCC) with high-level MET amplification (METamp): preclinical and clinical evidence. J Clin Oncol 39(3_suppl):329

Article  Google Scholar 

Le X et al (2021) Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp). J Clin Oncol 39(15):9021

Article  Google Scholar 

Park K et al (2019) Tepotinib in NSCLC patients harboring METex14 skipping: cohort A of phase II VISION study. Ann Oncol 30(9_suppl):ix22–ix23

Article  Google Scholar 

Lee J et al (2019) Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial. Cancer Discov 9(10):1388–1405

Article  PubMed  CAS  Google Scholar 

Turke AB, Zejnullahu K, Wu YL et al (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17:77–88

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu YL, Soo RA, Locatelli G, Stammberger U, Scagliotti G, Park K (2017) Does cMet remain a rational target for therapy in patients with EGFR TKI resistant non-small cell lung cancer? Cancer Treat Rev 61:70–81

Article  PubMed  CAS  Google Scholar 

Remon J, Morán T, Majem M et al (2014) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant nonsmall cell lung cancer: a new era begins. Cancer Treat Rev 40:93–101

Article  PubMed  CAS  Google Scholar 

Lin JJ, Johnson T, Lennerz JK et al (2020) Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer. J Clin Oncol 38(suppl 15):9611

Article  Google Scholar 

Awad MM, Liu S, Rybkin II et al (2021) Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med 384(25):2382–2393

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dagogo-Jack I, Yoda S, Lennerz JK et al (2020) MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin Cancer Res 26:2535–2545

Article  PubMed  PubMed Central  CAS  Google Scholar 

Daniel SL, Marni BT et al (2022) Partial treatment response to capmatinib in MET-amplified metastatic intrahepatic cholangiocarcinoma: case report & review of literature. Cancer Biol Ther 23(1):112–116

Article  Google Scholar 

Anthony T, Clotilde D, Valerie G et al (2023) Response to capmatinib in a MET fusion-positive cholangiocarcinoma. Oncologist 28:80–83

Article  Google Scholar 

Gao J et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):l1

Article  Google Scholar